Executive Director, Singapore Translational Cancer Consortium;
Deputy Director & Senior Principal Investigator, Cancer Science Institute of Singapore, NUS;
Provost’s Chair & Professor, Yong Loo Lin School of Medicine, National University of Singapore;
Director, National University Cancer Institute, Singapore (NCIS);
Head and Senior Consultant, Division of Haematology, Department of Haematology-Oncology, NCIS;
Leader, Haematologic Malignancy Tumour Group, NCIS
Profess Chng Wee Joo is the Executive Director of the Singapore Translational Cancer Consortium. He obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. He completed his Fellowship training in haematology in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics.
He is a member of many international professional committees, such as American Society of Haematology Scientific Committee on Plasma Cell Neoplasia, the International Myeloma Working Group and the Asian Myeloma Network. He is also involved in a number of Grant Review Committees, Conference Organising Committee, Advisory Boards and Steering Committees of Global Clinical Trials. He has authored more than 200 publications in many reputed journals, and actively participates in clinical trials and has delivered talks in many national and international conferences. He has won multiple awards for his research both locally and internationally including the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.
Professor Chng’s current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.
Prof Lim Soon Thye
Co-Director, Singapore Translational Cancer Consortium; Deputy Group Chief Executive Officer (Research & Education) Singapore Health Services;
Deputy Medical Director (Clinical), National Cancer Centre Singapore;
Senior Associate Dean, MD Programme, Duke-NUS Medical School
Professor Lim Soon Thyegraduated from the National University of Singapore and subsequently obtained his membership with the Royal College of Physician (UK). He received specialist training in medical oncology at the National Cancer Centre Singapore and further training in lymphoid malignancies at the University of Southern California. Currently, he is a senior consultant and deputy medical director (clinical) at NCCS. He also heads Singhealth-DukeNUS Blood Cancer Centre and a regular rank professor at Duke-NUS medical school.
His other leadership roles and positions include serving as the chairman of the Singhealth Central Institutional Review Board-B, director of ACP Oncology Clinical Service, chairman of the cancer service line development and chairman of the national medical oncology residency advisory committee. Additionally, he is also the current associate Dean for Clinical Education at Duke-NUS medical school. Prof Lim previously served as the president of the Singapore Society of Oncology from 2006 to 2010, and chairman of the chapter of Medical Oncologist, Academy of Medicine Singapore from 2010 to 2014. He is an active council member at the Singapore Cancer Society (SCS) where he also chairs the SCS medical professional and audit committee as well as the cancer treatment fund committee.
Prof Lim’s research focus is on lymphoid malignancies; in particular T and NK/T cell lymphomas, that occur more frequently in Asia. He has published more than 100 papers in high impact international journals such as Cancer Cell, Lancet Oncology and Journal of Clinical Oncology. He is the co-founder of the Asian Lymphoma Study Group, which includes academic medical centres across Asia.
Prof Lim was also the Principal Lead Investigator of a Translational and Clinical Research (TCR) Flagship Programme, Large Collaborative Grant (LCG) funded by NMRC (National Lymphoma Translational Research Program: From Genomics to Therapeutics from 2014 to 2019; Singapore lYMPHhoma TranslatiONal studY from 2019-2024).
Additionally, his team leads the blood cancer (T cell lymphoma) genomics project at the International Cancer Genomics Consortium. His group has been successful in securing more than S$20 million of NMRC, industrial and philanthropic funding over the years. His research efforts won him the 3rd Kobayashi Foundation Award in May 2014 in Taipei. This award was created to recognize distinguished research achievements in the field of cancer in Asian countries. Previously, he was also awarded Singhealth Distinguished Young leader Award in 2011. In 2015, he is also conferred the title of Tanoto Professorship in Medical Oncology. More recently, he is also part of an international team that won the American Association of Cancer Research (AACR) Team Science Award. The AACR Team Award is a prestigious award that recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that advances our fundamental knowledge of cancer.
Mr Clarence Khoo
Mr Clarence Khoo is the Director of Operations and Strategy with the Singapore Translational Cancer Consortium. A clinical pharmacist by training, he is experienced in clinical development, project management and regulatory affairs, having worked in multinational pharmaceutical companies, hospitals and the Singapore regulatory agency. In the roles in the pharmaceutical industry, he has had responsibilities for the planning and operationalisation of regional as well as global clinical studies (early phase to late phase development programmes and non-interventional studies).